Anticoagulant Micrurus venoms: Targets and neutralization.
Acetates
/ pharmacology
Animals
Anticoagulants
/ toxicity
Blood Coagulation
/ drug effects
Coral Snakes
Elapid Venoms
/ antagonists & inhibitors
Humans
Indoles
/ pharmacology
Keto Acids
Mice
Phospholipase A2 Inhibitors
/ pharmacology
Receptors, Phospholipase A2
/ drug effects
Snake Bites
/ drug therapy
Species Specificity
Thromboplastin
/ metabolism
Whole Blood Coagulation Time
Coral snake
Elapid coagulotoxicity
Prothrombinase inhibition
Snakebite treatment
Varespladib
Journal
Toxicology letters
ISSN: 1879-3169
Titre abrégé: Toxicol Lett
Pays: Netherlands
ID NLM: 7709027
Informations de publication
Date de publication:
01 Feb 2021
01 Feb 2021
Historique:
received:
20
08
2020
revised:
30
10
2020
accepted:
09
11
2020
pubmed:
17
11
2020
medline:
12
1
2021
entrez:
16
11
2020
Statut:
ppublish
Résumé
Snakebite is a neglected tropical disease with a massive global burden of injury and death. The best current treatments, antivenoms, are plagued by a number of logistical issues that limit supply and access in remote or poor regions. We explore the anticoagulant properties of venoms from the genus Micrurus (coral snakes), which have been largely unstudied, as well as the effectiveness of antivenom and a small-molecule phospholipase inhibitor-varespladib-at counteracting these effects. Our in vitro results suggest that these venoms likely interfere with the formation or function of the prothrombinase complex. We find that the anticoagulant potency varies widely across the genus and is especially pronounced in M. laticollaris. This variation does not appear to correspond to previously described patterns regarding the relative expression of the three-finger toxin and phospholipase A
Identifiants
pubmed: 33197555
pii: S0378-4274(20)30467-7
doi: 10.1016/j.toxlet.2020.11.010
pii:
doi:
Substances chimiques
Acetates
0
Anticoagulants
0
Elapid Venoms
0
Indoles
0
Keto Acids
0
Phospholipase A2 Inhibitors
0
Receptors, Phospholipase A2
0
micrurus venom
0
varespladib
2Q3P98DATH
Thromboplastin
9035-58-9
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
91-97Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.